Cytokinetics Secures Canadian Approval for MYQORZO in Hypertrophic Cardiomyopathy
Event summary
- Health Canada approved MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) on October 19, 2026.
- This marks the fifth regulatory approval for MYQORZO in less than a year, following U.S., China, EU, and UK approvals.
- The approval is based on positive Phase 3 SEQUOIA-HCM trial results showing significant improvements in exercise capacity and symptoms.
- MYQORZO is a once-daily, oral cardiac myosin inhibitor designed to reduce LVOT obstruction in oHCM patients.
The big picture
Cytokinetics' rapid global regulatory approvals for MYQORZO underscore its strategic focus on addressing unmet needs in hypertrophic cardiomyopathy. The approval in Canada further solidifies MYQORZO's position as a potential standard of care for oHCM, a condition affecting approximately half of all HCM patients. The company's ability to leverage this momentum into broader market penetration and pipeline expansion will be critical for sustained growth.
What we're watching
- Market Expansion
- The pace at which Cytokinetics can secure additional regulatory approvals in other major markets.
- Clinical Pipeline
- Whether Cytokinetics can successfully expand MYQORZO's use to non-obstructive HCM and pediatric populations.
- Competitive Dynamics
- How MYQORZO's market acceptance will compare against existing and emerging therapies for HCM.
